Goldman Sachs Upgrades Taysha Gene Therapies on Rett Syndrome Potential

Goldman Sachs upgrades Taysha Gene Therapies to Buy with an $11 target, citing strong confidence in the company’s Rett syndrome program and REVEAL study expectations.